2009³â 10¿ù 8ÀÏ (¸ñ) : D1
Á¦1ȸÀÇÀå
Á¦2ȸÀÇÀå
Á¦3ȸÀÇÀå
Á¦4ȸÀÇÀå
Á¦5ȸÀÇÀå
Á¦6ȸÀÇÀå
Á¦7ȸÀÇÀå
ÄÁº¥¼Ç¼¾Å¸1Ãþ
10:30-12:30 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)1

1-5
°­Á¤Ã¤,±è°æ¼ö

6-10
±èÁ¤Çö,ȲÁø¿ë
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)2

21-25
¹Ú¿µ¹è,¾È¿µ±Ù

26-30
±ÇÇöö,ÀÌ»ó°ï
ÁßÀç½Ã¼ú1

41-45
Á¶¸íÂù,¹ÚÁ¾¼±

46-50
¹Ú½ÂÁ¤,¹ÚÇå½Ä
½ÉÆ÷Áö¿ò3
-ºÎÁ¤¸Æ-

Á¶Á¤°ü,À̸¸¿µ/±èÀ¯È£,±èÀ±³â
½ÉÆ÷Áö¿ò4
-¿µ»ó-

±èÀ±Çö,À̰æÇÑ
±âÃÊ¿¬±¸1

87-91
°í±¤°ï,ÀÓµµ¼±

92-96
±è´ö°æ,¹é»óÈ«
¼Ò¾Æ1
±¸¿¬&Key Note

115-118
±ÇÅÂÂù,±èöȣ
Æ÷½ºÅÍ ¹ßÇ¥ 1
10:30-18:00

(1~97)
12:30-14:00 Satellite
Symposium 1
-»ç³ëÇǾƺ¥Æ¼½º-

±èÀçÇü,±è¿µÁ¶
Satellite
Symposium 2
-Çѹ̾àǰ-

Á¶½Â¿¬,±èöȣ
Satellite
Symposium 3
-´ÙÀÌÀÌÂî»êÄì & ´ë¿õÁ¦¾à-

½ÉºÀ¼·,±è´ö°æ
Satellite
Symposium 4
-µ¿¾ÆÁ¦¾à-

È«ÅÃÁ¾,Á¶¸íÂù
½ÉÆ÷Áö¿ò5-1
-¼Ò¾Æ½ÉÀå-

³ëÁ¤ÀÏ,ÀÌÁÖ¿ø
14:00-15:30 Clinical Research Award1
1-6
ÀüÀº¼®,±èµ¿¿î/½É»çÀ§¿ø:±ÇÁØ,±è¿µ±Ç,±è¿µ´ë,ÀüÈñ°æ,Çö¹Î¼ö
Clinical Research Award2
7-12
¿Àº´Èñ,Â÷ÅÂÁØ/½É»ç:¹Ú´ë±Õ,¼ÛÀç°ü,¿Àµ¿Áø,伺ö,ȲÈï°ï
½ÉÆ÷Áö¿ò1
-ÇãÇ÷¼º½ÉÁúȯ-

½Å¿µ¿ì,·ù¿Õ¼º
½ÉºÎÀü1

51-54
±è±â½Ä,±èÀçÁß

55-58
¹é»óÈ«,ÃÖµ¿ÁÖ
ÃÊÀ½ÆÄ1

69-72
Àå°æ½Ä,¼Õ´ë¿ø

73-76
Á¤»ó¸¸,±è¼ø±æ
ºÎÁ¤¸Æ1

97-100
±è¼º¼ø,ÃÖÀμ®

101-104
±èÀ±³â,°ûÃæÈ¯
¼Ò¾Æ2
±¸¿¬&Key Note

119-122
¹Ú¿µºÀ,À̱¤¼÷
15:30-16:00 Coffee Break Æ÷½ºÅͱ¸¿¬ 1
15:30-16:30

(1~6)
(7~12)
ÀüµÎ¼ö,Á¤°æÅÂ
16:00-18:00 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)3

11-15
±Ç¿µÁÖ,¹Ú½ÃÈÆ

16-20
¿Àµ¿ÁÖ,³ªµæ¿µ
ÁßÀç½Ã¼ú2

31-35
¹Ú¼º¿í,ÀÓµµ¼±

36-40
È«ÅÃÁ¾,ÀÌöȯ
½ÉÆ÷Áö¿ò2
- ±âÃÊ-

¹ÚÁ¤ÀÇ,±èÄ¡Á¤
½ÉºÎÀü2

59-63
±è¿µ±Ç,¹Ú½Â¿ì

64-68
¼­È«¼®,ÀüÀº¼®
ÃÊÀ½ÆÄ2

77-81
À强±¹,±ÇÁØ

82-86
¹ÚÁ¾Ãá,À±È£Áß
ºÎÁ¤¸Æ2

105-109
Á¶¿ë±Ù,³²±âº´

110-114
½Åµ¿±¸,Â÷ÅÂÁØ
½ÉÆ÷Áö¿ò5-2
Special Lecture and Symposium

¹ÚÀμ÷,ÀÌ»óÈ£
2009³â 10¿ù 9ÀÏ(±Ý) : D2        07:00-08:00 ÆòÀÇ¿øÈ¸ (ÄÁº¥¼Ç¼¾ÅÍ 3Ãþ ´ÙÀ̾ƸóµåȦ)
Á¦1ȸÀÇÀå Á¦2ȸÀÇÀå Á¦3ȸÀÇÀå Á¦4ȸÀÇÀå Á¦5ȸÀÇÀå Á¦6ȸÀÇÀå Á¦7ȸÀÇÀå ÄÁº¥¼Ç¼¾Å¸ 1Ãþ
08:00-09:30 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)4

123-126
ÀÌÀç¿ì,±èº´¿Á

127-130
ÀÌ¸í¹¬,±è»ó¿í
ÁßÀç½Ã¼ú3

157-160
±è¼º±¸,À̽Âȯ

161-164
Á¤¸íÈ£,Á¶º´·Ä
½ÉÆ÷Áö¿ò6
-°íÇ÷¾Ð-

ÀüÀçÀº,±èöȣ
½ÉÆ÷Áö¿ò8
-¿Ü°ú-

ÀÌ¿µÅ¹,ÀÌÀç¿ø
ÃÊÀ½ÆÄ3

207-210
Á¤³²½Ä,±è¿øÈ£

211-214
Á¤Áø¿ø,½Å±æÀÚ
ºÎÁ¤¸Æ3

241-244
¿Àµ¿Áø,¿À¼¼ÀÏ

245-248
±èÀ¯È£,±è´ë°æ
¼Ò¾Æ3
±¸¿¬&Key Note

273-276
ÀÌ»ó¹ü,¹Ú¿µÈ¯
Æ÷½ºÅÍ ¹ßÇ¥ 2
08:00-18:00
(98~199)
09:30-10:00 Coffee Break Æ÷½ºÅͱ¸¿¬ 2
09:00-10:00

(13~18)
(19~24)
ÀÌÀç¿õ,À¯±âµ¿
10:00-12:00 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)5

131-135
Á¶½Â¿¬,ÃÖµ¿ÁÖ

136-140
Çã½ÂÈ£,Áøµ¿±Ô
ÁßÀç½Ã¼ú4

165-169
Á¤¿í¼º,±è¸í°ï

170-174
ÇѱԷÏ,ÀÌ»óÈÆ
ÀþÀº1(±âÃÊ)

1-5
¹ÚÁ¤ÀÇ,±è°æ¼ö/½É»ç:±è´ö°æ,·ù¿Õ¼º,¼­È«¼®,Á¤À͸ð,ÇѱâÈÆ

ÀþÀº2(ÀÓ»ó)

6-10
ÀÌ¸í¹¬,¹Úâ±Ô/½É»ç:°­¼®¹Î,±èÄ¡Á¤,¹ÚÁ¤¹è,ÀÓµµ¼±,ÀÓ¼¼Áß

¿µ»ó1

215-224
ÃÖ¿¬Çö,Á¤Çؾï
ºÎÁ¤¸Æ4

249-253
Á¶Á¤°ü,ÃÖ±âÁØ

254-258
±è¿µÈÆ,À̹®Çü
¼Ò¾Æ4
Special Lecture&±¸¿¬&Key Note

277-282
ÀÌÇØ¿ë,±è³²¼ö
12:00-12:40 Plenary Session 1 (1~3ȸÀÇÀå)
13:00-14:30 Satellite
Symposium 5
-¾Æ½ºÆ®¶óÁ¦³×Ä«-

¹ÚÁ¤ÀÇ,À¯±ÔÇü
Satellite
Symposium 6
-Á¾±Ù´ç-

±èÀçÇü,ÀÌ¸í¹¬
Satellite
Symposium 7
-Çѱ¹È­ÀÌÀÚ-

½Â±â¹è,±èÈ¿¼ö
Satellite
Symposium 8
-Çѱ¹³ë¹ÙƼ½º-

¿Àº´Èñ,伺ö
Satellite
Symposium 9
-Çѱ¹¿ÀÃ÷Ä«Á¦¾à-

Á¤³²½Ä,¹Ú¼º¿í
ÀÇ·á±â±â
¿¬¼ö°­ÁÂ
°£Çà¿öÅ©¼¥

Çã¼±,À±È£Áß
14:30-16:00 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)6

141-144
±èµ¿¼ö,±è¸í¾Æ

145-148
ÀÓÁ¾À±,À̰ÇÁÖ
ÁßÀç½Ã¼ú5

175-178
Àå¾ç¼ö,äÀÎÈ£

179-182
ʽÂÁ¦,ÃÖµ¿ÈÆ
ÁßÀç½Ã¼ú7

191-194
°íÀç±â,±èÈñ¿­

195-198
À±Á¤ÇÑ,Çö¹Î¼ö
½ÉÆ÷Áö¿ò9
-Ç÷°ü-

¿Àº´Èñ,±è±â½Ä
¿µ»ó2

225-232
ÀÌ»óö,±èÅÂÈÆ
°íÇ÷¾Ð1

259-265
Á¶¸íÂù,È«°æ¼ø
ÁöÁú´ë»çÁúȯ

283-289
½ÅÇöÈ£,±è»óÇö
Æ÷½ºÅͱ¸¿¬ 3
15:30-16:30


(25~32)
(33~36)
¼ºÁöµ¿,ÀÓ»ó¿í
16:00-16:30 Coffee Break
16:30-18:00 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)7

149-152
½ÅÀͱÕ,Â÷±¤¼ö

153-156
±ÇÇõ¹®,Àü±¹Áø
ÁßÀç½Ã¼ú6

183-186
±èÈ¿¼ö,È«¹ü±â

187-190
½É¿øÈì,°í¿µ¿±
½ÉÆ÷Áö¿ò7
-½ÉºÎÀü-

ÀÌ¸í¹¬,À¯±ÔÇü
±âÃÊ¿¬±¸2

199-202
ÇѱâÈÆ,¹ÚÇö¿µ

203-206
¿À±¸ÅÃ,À̹«¿ë
¿µ»ó3

233-240
±è¾ç¹Î,ÃÖº´¿í
°íÇ÷¾Ð2

266-272
¹Úâ±Ô,ÀÓ¼¼Áß
¿Ü°ú

290-296
±è±âºÀ,ÀÌ¿µÅ¹
2009³â 10¿ù 10ÀÏ (Åä) : D3
Á¦1ȸÀÇÀå Á¦2ȸÀÇÀå Á¦3ȸÀÇÀå Á¦4ȸÀÇÀå Á¦5ȸÀÇÀå Á¦6ȸÀÇÀå Á¦7ȸÀÇÀå ÄÁº¥¼Ç¼¾Å¸ 1Ãþ
08:30-10:30 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)8

297-301
ÁÖ½ÂÀç,À̳²È£

302-306
¹Ú±Ý¼ö,Áø½Â¿ø
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)9

317-321
±è¿µÁ¶,°íÃæ¿ø

322-326
±è¿µ´ë,À̼ºÀ±
ÁßÀç½Ã¼ú8

337-341
½Â±â¹è,±èµÎÀÏ

342-346
±èÁ¾Áø,Â÷ÅÂÁØ
ÃÊÀ½ÆÄ4

357-361
ÀÌÀç¿ì,¹Ú¼ºÈÆ

362-366
±è±Ç»ï,±è¿Ï
ºÎÁ¤¸Æ5

367-371
³ëÅÂÈ£,±èÁؼö

372-376
À̸¸¿µ,À̸í¿ë
±âŸÀÓ»óÁúȯ1

377-381
¹ÚÀÇÇö,ÀÓ¼¼Áß

382-386
ÀüÀçÀº,¹Ú½Â¿ì
±âÃÊ¿¬±¸3

397-401
Àå¾ç¼ö,±è¹«Çö

402-406
°í±Ô¿µ,±èÈ¿¼ö
Æ÷½ºÅÍ ¹ßÇ¥ 3
08:30~15:30
(200~292)
10:30-11:00 Coffee Break Æ÷½ºÅͱ¸¿¬4
10:00~11:00

(37~42)
(43~48)
¾ÈÁ¤Ãµ,Á¶¿íÇö
11:00-11:40 Plenary Session 2 (1~3ȸÀÇÀå)
11:40-13:30 ÃÑ È¸ (Á¡½É) 1-3ȸÀÇÀå
13:30-15:30 ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)10

307-311
±è±Ç¹è,°í¿µ¿±

312-316
È«°æÇ¥,Çã½ÂÈ£
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ
(°üµ¿¸ÆÁúȯ)11

327-331
¼ºÀÎȯ,äÁ¦°Ç

332-336
Â÷µ¿ÈÆ,ÃÖ¿µÁø
ÁßÀç½Ã¼ú9

347-351
¾ÈÅÂÈÆ,È«¸í±â

352-356
±è¹«Çö,ÀüÈñ°æ
½ÉÆ÷Áö¿ò10
-ÁßÀç½Ã¼ú-

¹Ú¿µ¹è,ʽÂÁ¦
½ÉÆ÷Áö¿ò11
-½ÉÃÊÀ½ÆÄ-

½É¿ÏÁÖ,¼ÛÀç°ü
±âŸÀÓ»óÁúȯ2

387-391
±èö¹Î,ÃÖÁö¿ë

392-396
Á¶ÁÖÈñ,³ª½Â¿î
±âÃÊ¿¬±¸4

407-411
Á¶¸íÂù,¼­È«¼®

412-416
Á¤À͸ð,¹ÚÇö¿µ
* 1~3ȸÀÇÀå: ÄÁº¥¼Ç 4Ãþ
* 4~5 ÄÁº¥¼Ç 3Ãþ(¿¡¸Þ¶öµåA,B)
* 6~7ȸÀÇÀå: º»°ü 2Ãþ (±×·£µåº¼·ë)
Plenary Session
2009³â 10¿ù 9ÀÏ (±Ý) ÁÂÀå: ½ÉºÀ¼·
12:00-12:40 Can Stent Thrombosis After Drug Eluting Stents be Prevented? circulation_85_1300_53.pdf David P. Faxon/ USA
2009³â 10¿ù 10ÀÏ (Åä) ÁÂÀå: ¹Ú¿µ¹è
11:00-11:40 Acute Coronary Syndromes: Pathophysiology and Management of an Inflammatory Disease Thomas F. Luscher/ Switzerland
½ÉÆ÷Áö¿ò
2009³â 10¿ù 8ÀÏ (¸ñ)
Á¦ 3ȸÀÇÀå
1. ÇãÇ÷¼º½ÉÁúȯ
14:00-15:30 Platelet: Biology, Assay & Resistance ÁÂÀå: ½Å¿µ¿ì, ·ù¿Õ¼º
14:00-14:20 1. Biology of Platelet circulation_88_1313_53.pdf ÁÖ½ÂÀç/Á¦ÁÖÀÇ´ë
14:20-14:40 2. Assay of Platelet Function & Cut Off Value of Resistance Against Anti-platelet Drugs circulation_88_1314_53.pdf Á¤¿µÈÆ/°æ»óÀÇ´ë
14:40-15:00 3. Pharmaco-genetics for Resistance Against Anti-Platelet Drugs circulation_88_1315_53.pdf ¼­Á¤¿ø/¼­¿ïÀÇ´ë
15:00-15:20 4. Clinical Implication of Resistance Against Anti-Platelet Drugs circulation_88_1316_53.pdf ÇÑÁÖ¿ë/¼º±Õ°üÀÇ´ë
15:20-15:30 5. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: ±è¹«Çö, ¹Ú°æ¿ì, À±Á¤ÇÑ, Çö¹Î¼ö
2. ±âÃÊ
16:00-18:00 Recent Change in Basic Cardiovascular Research (Review Course) ÁÂÀå: ¹ÚÁ¤ÀÇ, ±èÄ¡Á¤
16:00-16:25 1. ROS, Free Fatty Acids and diabetic vascular complication circulation_89_1319_53.pdf ¹ÚÁß¿­/¿ï»êÀÇ´ë
16:25-16:50 2. Ischemic Pre-conditioning and Post-conditioning circulation_89_1320_53.pdf ±ÇÇöö/¼º±Õ°üÀÇ´ë
16:50-17:15 3. Vascular Calcification : Active and Regulated Process in Vascular Disease circulation_89_1321_53.pdf Á¶ÇöÀç/¼­¿ïÀÇ´ë
17:15-17:40 4. Vascular Aging and Arteriosclerosis circulation_89_1322_53.pdf ±èÀç·æ/¿µ³²ÀÇ´ë
17:40-18:00 5. Áú¹® ¹× ÅäÀÇ ÆÐ³Î:¹ÚÇö¿µ, ¹é»óÈ«, ÇѱâÈÆ, Á¤À͸ð
Á¦ 4ȸÀÇÀå
3. ºÎÁ¤¸Æ
10:30-11:30 AF, from In-silico to Bedside ÁÂÀå: Á¶Á¤°ü, À̸¸¿µ
10:30-10:48 1. Non-linear Dynamics in Fibrillation circulation_87_1303_53.pdf À̰æÁø/°í·Á´ëÇб³
10:48-11:06 2. Spectrum Analysis in AF ¿À¼¼ÀÏ/¼­¿ïÀÇ´ë
11:06-11:24 3. Ablation Strategy for Chronic AF circulation_87_1305_53.pdf ³²±âº´/¿ï»êÀÇ´ë
11:24-11:30 4. Áú¹® ¹× ÅäÀÇ ÆÐ³Î : °ûÃæÈ¯, ±è³²È£
11:30-12:30 VT/ VF, Basics and Application ÁÂÀå: ±èÀ¯È£, ±èÀ±³â
11:30-11:48 1. LV and RV Anatomy for the Electrophysiologist ¼­Á¤¿í/¼­¿ïÀÇ´ë
11:48-12:06 2. Pathology of VT/VF in Structural Heart Disease Á¶¿ë±Ù/°æºÏÀÇ´ë
12:06-12:24 3. VT Ablation in Prior Myocardial Infarction Chun Hwang/USA
12:24-12:30 4. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: ¹ÚÈñ³², Â÷ÅÂÁØ
Á¦ 5ȸÀÇÀå
4. ¿µ»ó
10:30-12:30 Recent Advancements in Cardiac Imaging ÁÂÀå: ±èÀ±Çö, À̰æÇÑ
10:30-10:50 1. Recent Updates in Cardiac MDCT & MRI Ã߱⼮/ºÎ»êÀÇ´ë
10:50-11:10 2. Fusion of Myocardial SPECT and CT Angiography to Diagnose Ischemic Heart Disease circulation_90_1326_53.pdf ÀÓ¼®ÅÂ/ÀüºÏ´ëÇб³
11:10-11:30 3. Cardiac MRI for Ischemic Heart Disease circulation_90_1327_53.pdf ±è¿µÁø/¿¬¼¼ÀÇ´ë
11:30-11:50 4. Imaging of Atheromatous Plaque Using Nuclear Medicine Technique circulation_90_1328_53.pdf ¿©Á¤¼®/µ¿±¹´ëÇб³
11:50-12:10 5. Post-treatment Follow-up CTCA circulation_90_1329_53.pdf ÀüÀºÁÖ/¼­¿ïÀÇ´ë
12:10-12:30 6. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: °­¿øÁØ, ¿ëȯ¼®, Á¤Á¤ÀÓ, ÃÖÁØ¿µ
Á¦ 7ȸÀÇÀå
5. ¼Ò¾Æ½ÉÀå(1)
12:30-14:00 Symposium 1
12:30-14:00 Childhood Origin of Atherosclerosis ÁÂÀå: ³ëÁ¤ÀÏ, ÀÌÁÖ¿ø
12:30-12:50 1. Childhood Origin of Atheroscleoris circulation_91_1333_53.pdf È«¿µ¹Ì/ÀÌÈ­ÀÇ´ë
12:50-13:10 2. Assessment of Endothelial Function and Its Clinical Application in Childhood circulation_91_1334_53.pdf Áø¼±¹Ì/À»ÁöÀÇ´ë
13:10-13:30 3. Treatment Strategies for Dyslipidemia in Childhood circulation_91_1335_53.pdf ÇÑÁöȯ/°¡Å縯ÀÇ´ë
13:30-14:00 4. ÅäÀÇ ÆÐ³Î: ¼Û¹Î¼·, ÇãÁØ, À±½Å¿ø(Áß¾Ó)
16:00-18:00 Special Lecture and Symposium 2
16:00-18:00 CHF: CHD Associated or Recent Advance ÁÂÀå: ¹ÚÀμ÷, ÀÌ»óÈ£
16:00-16:30 1. Revisit to Some Basics of Blood Pressure circulation_110_1339_53.pdf Myung K. Park/USA
16:30-16:50 2. How Can We Integrate the Biomarker and Its Application in Pediatric CHF? circulation_110_1340_53.pdf ±è¿µÈÖ/¿ï»êÀÇ´ë
16:50-17:10 3. Myocardial Failure in Fontan Circulation circulation_110_1341_53.pdf ±è¼öÁø/ºÎõ¼¼Á¾º´¿ø
17:10-17:30 4. Surgical Management as a Bridge to Transplantation in Children with Refractory CHF circulation_110_1342_53.pdf ¾çÁöÇõ/¼º±Õ°üÀÇ´ë
17:30-18:00 5. ÅäÀÇ Panel: ¹ÚÁ¤ÁØ, °­À̼®, Çö¸íö
Key Note and Free Paper
10:30-11:30 Key Note 1-3 & Free Paper (1) ÁÂÀå: ÀÌÈïÀç, ±è¿ëÁø
10:30-10:50 1. Late Hypertension in Patients with Successfully Repaired CoA circulation_92_1345_53.pdf ±è±â¹ü/¼­¿ïÀÇ´ë
10:50-11:10 2. Brain Outcome After Surgery for CHD: Patient and Perioperative Factors circulation_92_1346_53.pdf äÁ¾Èñ/¼­¿ïÀÇ´ë
11:10-11:30 3. Surgical Strategies to Minimize Morbidity in OR and ICU circulation_92_1347_53.pdf À±ÅÂÁø/¿ï»êÀÇ´ë
11:30-12:30 Free Paper(1) ÁÂÀå: ±ÇÅÂÂù, ±èöȣ
Panel: ¼Õ¼¼Á¤, ¼ÛÁø¿µ, ±è½ÃÈ£
14:00-15:30 Key Note 4-5 & Free Paper (2) ÁÂÀå: ±è¼ºÈ£(Á¦ÁÖÇѶ󺴿ø)
14:00-14:20 4. What a hot in intervention circulation_111_1350_53.pdf ÃÖÀ翵/¿¬¼¼ÀÇ´ë
14:20-14:40 5. ¿Ü±¹ ¼±Ãµ¼º ½ÉÀ庴 ȯÀÚ Áö¿ø ÇöȲ ºÐ¼® ¹× ÇâÈÄ Áö¿ø ¹æ½Ä¿¡ ´ëÇÑ Á¦¾È circulation_111_1351_53.pdf ¹ÚÀμ÷/¿ï»êÀÇ´ë
14:40-15:30 Free Paper(2) ÁÂÀå: ¹Ú¿µºÀ, À̱¤¼÷
Panel: Á¤Á¶¿ø, ÀÌâÇÏ, Á¤¹ÌÁø
2009³â 10¿ù 9ÀÏ (±Ý)
Á¦ 3ȸÀÇÀå
6. °íÇ÷¾Ð
08:00-09:30 Considerations in the Management of Hypertension ÁÂÀå: ÀüÀçÀº, ±èöȣ
08:00-08:20 1. Hypertension with Obesity circulation_96_1373_53.pdf ±è¹Î±Ô/ÇѸ²ÀÇ´ë
08:20-08:40 2. Hypertension with Pregnancy circulation_96_1374_53.pdf ¹®À翬/Æ÷õÁß¹®ÀÇ´ë
08:40-09:00 3. Hypertension with Very Elderly Patients circulation_96_1375_53.pdf ±è±¤ÀÏ/¼­¿ïÀÇ´ë
09:00-09:20 4. Non-invasive Hemodynamic Test in Hypertensive Patients circulation_96_1376_53.pdf ÇѽÂȯ/°¡ÃµÀÇ´ë
09:20-09:30 5. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: ±èµ¿¼ö, ±èµ¿¿î, ±èÇü¼·, ¹Úâ±Ô
7. ½ÉºÎÀü
16:30-18:00 Challenging Issues in the Management of Chronic Heart Failure ÁÂÀå: ÀÌ¸í¹¬, À¯±ÔÇü
16:30-16:50 1. Heart Failure with COPD circulation_94_1361_53.pdf ÀüÈñ°æ/°¡Å縯ÀÇ´ë
16:50-17:10 2. Heart Failure on Dialysis circulation_94_1362_53.pdf ȲÁø¿ë/°æ»óÀÇ´ë
17:10-17:30 3. How Should We Manage Blood Pressure in Heart Failure circulation_94_1363_53.pdf Á¤¿íÁø/°¡ÃµÀÇ´ë
17:30-17:50 4. How Should We Treat Heart Failure with Diastolic Dysfunction? circulation_94_1364_53.pdf ¹ÚÀçÇü/Ãæ³²ÀÇ´ë
17:50-18:00 5. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: °­¼®¹Î, Áøµ¿±Ô, È«±×·ç
Á¦ 4ȸÀÇÀå
8. ½ÉÀåÇ÷°ü¿Ü°ú
08:00-09:30 ECMO (Extracorporeal Membrane Oxygenation) Support ÁÂÀå: ÀÌ¿µÅ¹, ÀÌÀç¿ø
08:00-08:20 1. Indication and Practical Application of ECMO circulation_95_1367_53.pdf ±èÇü¼ö/ÇѸ²´ëÇб³
08:20-08:40 2. Management of Complications During ECMO circulation_95_1368_53.pdf À±¿µ³²/¿¬¼¼ÀÇ´ë
08:40-09:00 3. PCPS in Non-surgical Conditions circulation_95_1369_53.pdf ¼Û¿µºó/¼º±Õ°üÀÇ´ë
09:00-09:20 4. ECMO in Children circulation_95_1370_53.pdf ¹ÚÁ¤ÁØ/¿ï»êÀÇ´ë
09:20-09:30 5. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: Á¤Ã¶Çö ,¼ÛÇö, ¹Ú°èÇö
9. Ç÷°ü¿¬±¸È¸
14:30-16:00 Venous Thromboembolism ÁÂÀå: ¿Àº´Èñ, ±è±â½Ä
14:30-14:45 1. Genetic Test for the Better Outcome of VTE? circulation_93_1354_53.pdf À±¼º¼ö/¼­¿ïÀÇ´ë
14:45-15:00 2. Evolution of Anticoagulation Therapy circulation_93_1355_53.pdf ±èÀ念/¿¬¼¼¿øÁÖÀÇ´ë
15:00-15:15 3. Interventional Treatment of VTE: Radiologic Approach circulation_93_1356_53.pdf ÀÌÇØ±Ô/°¡Å縯ÀÇ´ë
15:15-15:30 4. Surgical Approach of VTE circulation_93_1357_53.pdf ¹Î½Â±â/¼­¿ïÀÇ´ë
15:30-15:45 5. VTE in Pregnancy circulation_93_1358_53.pdf ¹ÚÁ¤¹è/°üµ¿ÀÇ´ë
15:45-16:00 6. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: ±èÈñÁø, À¯»ó¿ë, À庴ö, Á¤Çؾï
Á¦ 7ȸÀÇÀå
5. ¼Ò¾Æ½ÉÀå(2)
Special Lecture ÁÂÀå: ÁÖÂù¿õ
10:00-10:30 Pediatric Cardiology: Past, Present, and Future-My Journey circulation_114_1430_53.pdf Myung K. Park/USA
08:00-08:40 Key Note 6-7 & Free Paper (3) ÁÂÀå: °íÀç°ï
08:00-08:20 6. Timing and Indication for Fontan circulation_97_1381_53.pdf ÀÌÇüµÎ/ºÎ»êÀÇ´ë
08:20-08:40 7. Management of PA and Intracardiac Problems at the Time of the Fontan circulation_97_1382_53.pdf ¹ÚÇѱâ/¿¬¼¼ÀÇ´ë
08:40-09:30 Free Paper(3) ÁÂÀå: ÀÌ»ó¹ü, ¹Ú¿µÈ¯
Panel: À¯ÀçÇö, ÀÌÀ翵, ÀÌ¿µ¼®
10:30-10:50 Key Note 8 &Free Paper (4) ÁÂÀå: ¼º½ÃÂù
10:30-10:50 8. Message from Longterm Outcomes in PA/VSD/MAPCAs circulation_112_1385_53.pdf ±è¿õÇÑ/¼­¿ïÀÇ´ë
10:50-12:00 Free Paper(4) ÁÂÀå: ÀÌÇØ¿ë, ±è³²¼ö
Panel: Àå±â¿µ, ÇÑÀçÁø, À¯°æÈñ
Korean Circulation Journal ±¹Á¦ÇмúÁö·ÎÀÇ µµ¾à
13:00-14:30 ÁÂÀå: Çã ¼±(ÇѸ²ÀÇ´ë, ÀÇÆíÇù Á¤º¸°ü¸®À§¿øÀå), À±È£Áß(´ëÇѽÉÀåÇÐȸ °£ÇàÀÌ»ç)
13:00-13:50 1. »õ³í¹®ÀÛ¼º¹ý(Reporting Guideline) circulation_113_1400_53.pdf ±è¼ö¿µ (ÇѸ²ÀÇ´ë, ÀÇÆíÇù ÃâÆÇÀ±¸®À§¿ø)
13:50-14:00 2. ÁúÀÇÀÀ´ä
14:00-14:30 3. Korean Circulation Journal ÀÌ SCI·Î °¡´Â ±æ Çã ¼± (ÇѸ²ÀÇ´ë, ÀÇÆíÇù Á¤º¸°ü¸®À§¿øÀå)
2009³â 10¿ù 10ÀÏ (Åä)
Á¦ 4ȸÀÇÀå
10. ÁßÀç½Ã¼ú
13:30-15:30 Drug Eluting Stent - A Close Look ÁÂÀå: ¹Ú¿µ¹è, ʽÂÁ¦
13:30-13:55 1. Specific Indication for DES & BMS: How to Choose circulation_98_1388_53.pdf ¾È¿µ±Ù/Àü³²ÀÇ´ë
13:55-14:20 2. The Efficacy of DES in Tough Subsets Such as Diabetes and CKD: How Well Does It Work? circulation_98_1389_53.pdf ÇѱԷÏ/ÇѸ²ÀÇ´ë
14:20-14:45 3. Comparison Between? SES, PES, ZES, and EES: Is There Difference? circulation_98_1390_53.pdf Çã½ÂÈ£/°è¸íÀÇ´ë
14:45-15:10 4. Innovative New DES's: Are They Promising? circulation_98_1391_53.pdf ±èº´¿Á/ÀÎÁ¦ÀÇ´ë
15:10-15:30 5. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: ±ÇÇöö, ±èÈ¿¼ö, ½Â±â¹è, Àå¾ç¼ö
Á¦ 5ȸÀÇÀå
11. ½ÉÃÊÀ½ÆÄ
13:30-15:30 Role of Echocardiography in Ischemic Heart Disease ÁÂÀå: ½É¿ÏÁÖ,¼ÛÀç°ü
13:30-13:50 1. Echocardiography for Acute Chest Pain ¹Ú½Â¿ì/¼º±Õ°üÀÇ´ë
13:50-14:10 2. Echocardiographic Evaluation of Coronary Flow À±È£Áß/°¡Å縯ÀÇ´ë
14:10-14:30 3. Stress Echocardiography: Pharmacologic vs. Exercise circulation_99_1396_53.pdf ¼ÛÁ¾¹Î/¿ï»êÀÇ´ë
14:30-14:50 4. Contrast Echocardiography ÀÓ¼¼Áß/¿¬¼¼ÀÇ´ë
14:50-15:10 5. Strain and Strain Rate Imaging in Ischemic Heart Disease Á¶±¸¿µ/¼­¿ïÀÇ´ë
15:10-15:30 6. Áú¹® ¹× ÅäÀÇ ÆÐ³Î: ¹Ú¼º¹Ì, ±è¿ì½Ä, À̰æÁø, ½ÅÁØÇÑ, À¯³²Áø
Satellite Symposium
2009³â 10¿ù 8ÀÏ (¸ñ)
1. »ç³ëÇǾƺ¥Æ¼½º [1ȸÀÇÀå]
New perspective on cardiovascular disease ÁÂÀå: ±èÀçÇü,±è¿µÁ¶
1. Recent Clinical Trial Data on CV Outcomes of Irbesartan in AF Patients:ACTIVE -i ±èÈ¿¼ö/¼­¿ïÀÇ´ë
2. Optimal Dosing of Antiplatelet Therapy in Patients With ACS undergoing an Early Invasive Strategy: Insights From the CURRENT (OASIS 7) Trial David P. Faxon/USA
3. Q&A
2. Çѹ̾àǰ [1ȸÀÇÀå]
Current Issue in Antihypertensive Therapy ÁÂÀå: Á¶½Â¿¬,±èöȣ
1. New Trend of Antihypertensive Therap circulation_102_1406_53.pdf ¹Úâ±Ô/°í·ÁÀÇ´ë
2. Clinical Trial Results for Amosartan circulation_102_1407_53.pdf Frans HH Leenen/Canada
3. ´ÙÀÌÀÌÂî»êÄì & ´ë¿õÁ¦¾à [3ȸÀÇÀå]
Treatment in HTN Patients with Metabolic Syndrome ÁÂÀå: ½ÉºÀ¼·,±è´ö°æ
1. Prevalence and Characteristics of Metabolic Syndrome in Korean Hypertension Patients circulation_100_1408_53.pdf ¹é»óÈ«/°¡Å縯ÀÇ´ë
2. OMEGA Study; The Relationship Between CVD, Metabolic SYndrome and BP(TBD) circulation_100_1409_53.pdf Tamio Teramoto/Japan
4. µ¿¾ÆÁ¦¾à [4ȸÀÇÀå]
Atorvastatin Original/ Generic °£ ÀÓ»óÀû È¿°ú ºñ±³ ÁÂÀå: È«ÅÃÁ¾,Á¶¸íÂù
1. ÀÌ»óÁöÁúÇ÷ÁõÀÇ ÃÖ½ÅÁö°ß circulation_103_1410_53.pdf ±è»óÇö/¼­¿ïÀÇ´ë
2. ÀÌ»óÁöÁúÇ÷Áõ ȯÀÚ¿¡°Ô¼­ Atorvastatin 20mgÀÇ Original/ Generic Á¦Ç° »çÀÌÀÇ ¾ÈÀü¼º ¹× À¯È¿¼º ºñ±³ ÀÓ»ó°á°ú circulation_103_1411_53.pdf À±¸íÈ£/¾ÆÁÖÀÇ´ë
2009³â 10¿ù 9ÀÏ (±Ý)
¾Æ½ºÆ®¶óÁ¦³×Ä« [1ȸÀÇÀå]
Optimal Management of Cardiovascular Disase ÁÂÀå: ¹ÚÁ¤ÀÇ,À¯±ÔÇü
1. Effective Management of Severe Hypertension with High Dose Candesartan: CEASAR Study circulation_105_1412_53.pdf ÃÖµ¿ÈÆ/¿¬¼¼ÀÇ´ë
2. The Role of Statins in Decreasing the Risk of Acute Events in a Patient with Coronary Artery Disease circulation_105_1413_53.pdf James Liao/USA
Á¾±Ù´ç [2ȸÀÇÀå]
New Treatment Option for Atorvastatin ÁÂÀå: ±èÀçÇü,ÀÌ¸í¹¬
1. Statin Overview circulation_106_1414_53.pdf ±èµ¿¿î/ÃæºÏÀÇ´ë
2. KoLipilou Study circulation_106_1415_53.pdf ±è»óÇö/¼­¿ïÀÇ´ë
È­ÀÌÀÚ [3ȸÀÇÀå]
New Approach for Korean Patients on Statin Therapy ÁÂÀå: ½Â±â¹è,±èÈ¿¼ö
1. Patient-tailored Statin Therapy in Achieving LDL-C Targets in Korean Patients circulation_107_1417_53.pdf ÀÌöȯ/¿ï»êÀÇ´ë
2. Case Review: Statin High Dose in Korean Patients circulation_107_1419_53.pdf Çã½ÂÈ£/°è¸íÀÇ´ë
3. Panel Discussion ÆÐ³Î: ±èµÎÀÏ, ÃÖµ¿ÁÖ
³ë¹ÙƼ½º [4ȸÀÇÀå]
Attaining Greater BP Reductions and Organ Protection: Current Strategies and Future Priorities ÁÂÀå: ¿Àº´Èñ,伺ö
1. A Journey to the Best ARB for Koreans circulation_104_1421_53.pdf °­´öÇö/¿ï»êÀÇ´ë
2. Combination Therapy for Hypertension in High-risk Patients circulation_104_1422_53.pdf Kenneth A. Jamerson/USA
3.Q&A
Çѱ¹¿ÀÃ÷Ä«Á¦¾à [5ȸÀÇÀå]
Antiplatelet Therapy in Diabetic Cardiovascular Disease; The Appraisal of Cilostazol ÁÂÀå: Á¤³²½Ä,¹Ú¼º¿í
1. Clinical and Prognostic Relevance of Diabetes Mellitus in Cardiovascular Disease; The Benefits of Antiplatelet Therapy to prevent Vascular Event circulation_108_1424_53.pdf ¹èÀåÈ£/°Ç¾çÀÇ´ë
2. Additive or Adjunctive Role of Cilosatzol in Diabetic Patients with High Platelet REactivity After PCI circulation_108_1425_53.pdf ±è¸í°ï/°æÈñÀÇ´ë
3. The Role of Cilostazol in Diabetic Patients Undergoing PCI circulation_108_1426_53.pdf À̽Âȯ/¿ï»êÀÇ´ë
4. Discussion ÆÐ³Î: ¼­Á¤¿ø, ¾È¿µ±Ù, Á¤¿µÈÆ
logo Çмú´ëȸÀÏÁ¤ »çÀüµî·Ï¾È³» Ãʷϵî·Ï¾È³» Ãʷϵî·Ï/°ü¸® ¼÷¹Ú ¹× ±³Åë ¾È³» Àü½Ã¾È³»